SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001549595-23-000032
Filing Date
2023-04-13
Accepted
2023-04-13 16:04:29
Documents
63
Period of Report
2023-02-28

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-20230228.htm   iXBRL 10-Q 1256175
2 EX-31.1 nrix-20230228xex311.htm EX-31.1 10951
3 EX-31.2 nrix-20230228xex312.htm EX-31.2 10941
4 EX-32.1 nrix-20230228xex321.htm EX-32.1 8526
  Complete submission text file 0001549595-23-000032.txt   5316402

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20230228.xsd EX-101.SCH 37715
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nrix-20230228_cal.xml EX-101.CAL 43880
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nrix-20230228_def.xml EX-101.DEF 174255
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20230228_lab.xml EX-101.LAB 485202
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20230228_pre.xml EX-101.PRE 308364
57 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20230228_htm.xml XML 599413
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 23818382
SIC: 2834 Pharmaceutical Preparations